Literature DB >> 24665835

MicroRNA-mediated regulation of melanoma.

V Sun1, W B Zhou, S Majid, M Kashani-Sabet, A A Dar.   

Abstract

Melanoma is one of the most aggressive and deadly skin cancers, and, in its advanced stages, accounts for > 80% mortality. The incidence of melanoma is increasing worldwide; however, beyond surgical removal of the tumour, there is currently no curative therapy available, especially for its advanced stages. This may, in part, be owing to incomplete understanding of the molecular mechanisms that regulate the initiation and/or progression of melanoma to metastasis. The molecular mechanisms leading to the development and progression of melanoma are the focus of intense investigation, and many genetic/epigenetic alterations affecting melanoma progression and development have been identified. microRNAs (miRNAs) are emerging as important causal modulators in the development and progression of melanoma. The understanding of miRNA-mediated regulation of tumours has grown immensely over the last few years, as it has been understood to regulate most biological processes. Here, we review the currently available data on miRNAs associated with melanoma, highlighting those deregulated miRNAs that target important genes and pathways involved in the progression of melanocytes to primary and metastatic melanoma. We also review their potential clinical utility as biomarkers and potential use in targeted therapy.
© 2014 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24665835     DOI: 10.1111/bjd.12989

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

1.  Effects of microRNA-708 on Epithelial-Mesenchymal Transition, Cell Proliferation and Apoptosis in Melanoma Cells by Targeting LEF1 through the Wnt Signaling Pathway.

Authors:  Xiao-Fei Song; Qi-Hua Wang; Ran Huo
Journal:  Pathol Oncol Res       Date:  2017-11-14       Impact factor: 3.201

2.  Curcumin Inhibits the Growth and Metastasis of Melanoma via miR-222-3p/SOX10/Notch Axis.

Authors:  Youqun Tang; Yanming Cao
Journal:  Dis Markers       Date:  2022-05-09       Impact factor: 3.464

3.  Melanoma miRNA trafficking controls tumour primary niche formation.

Authors:  Shani Dror; Laureen Sander; Hila Schwartz; Danna Sheinboim; Aviv Barzilai; Yuval Dishon; Sebastien Apcher; Tamar Golan; Shoshana Greenberger; Iris Barshack; Hagar Malcov; Alona Zilberberg; Lotan Levin; Michelle Nessling; Yael Friedmann; Vivien Igras; Ohad Barzilay; Hananya Vaknine; Ronen Brenner; Assaf Zinger; Avi Schroeder; Pinchas Gonen; Mehdi Khaled; Neta Erez; Jörg D Hoheisel; Carmit Levy
Journal:  Nat Cell Biol       Date:  2016-08-22       Impact factor: 28.824

Review 4.  MicroRNA-Directed Cancer Therapies: Implications in Melanoma Intervention.

Authors:  Anita Thyagarajan; Ahmed Shaban; Ravi Prakash Sahu
Journal:  J Pharmacol Exp Ther       Date:  2017-10-20       Impact factor: 4.030

5.  The differential expression of micro-RNAs 21, 200c, 204, 205, and 211 in benign, dysplastic and malignant melanocytic lesions and critical evaluation of their role as diagnostic biomarkers.

Authors:  Katherine Quiohilag; Peter Caie; Anca Oniscu; Thomas Brenn; David Harrison
Journal:  Virchows Arch       Date:  2020-05-09       Impact factor: 4.064

6.  Demethylation by low-dose 5-aza-2'-deoxycytidine impairs 3D melanoma invasion partially through miR-199a-3p expression revealing the role of this miR in melanoma.

Authors:  Cécile Desjobert; Arnaud Carrier; Audrey Delmas; Diego M Marzese; Antoine Daunay; Florence Busato; Arnaud Pillon; Jörg Tost; Joëlle Riond; Gilles Favre; Chantal Etievant; Paola B Arimondo
Journal:  Clin Epigenetics       Date:  2019-01-16       Impact factor: 6.551

7.  Downregulation of intratumoral expression of miR-205, miR-200c and miR-125b in primary human cutaneous melanomas predicts shorter survival.

Authors:  Beatriz Sánchez-Sendra; Carolina Martinez-Ciarpaglini; José F González-Muñoz; Amelia Murgui; Liria Terrádez; Carlos Monteagudo
Journal:  Sci Rep       Date:  2018-11-20       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.